JP2023545432A5 - - Google Patents

Info

Publication number
JP2023545432A5
JP2023545432A5 JP2023521682A JP2023521682A JP2023545432A5 JP 2023545432 A5 JP2023545432 A5 JP 2023545432A5 JP 2023521682 A JP2023521682 A JP 2023521682A JP 2023521682 A JP2023521682 A JP 2023521682A JP 2023545432 A5 JP2023545432 A5 JP 2023545432A5
Authority
JP
Japan
Prior art keywords
amino acid
product according
pharmaceutical product
approximately
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023521682A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023545432A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/054084 external-priority patent/WO2022076767A1/en
Publication of JP2023545432A publication Critical patent/JP2023545432A/ja
Publication of JP2023545432A5 publication Critical patent/JP2023545432A5/ja
Pending legal-status Critical Current

Links

JP2023521682A 2020-10-11 2021-10-08 191p4d12タンパク質に結合する抗体薬物コンジュゲート(adc)を用いたがんの治療のための方法 Pending JP2023545432A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063090272P 2020-10-11 2020-10-11
US63/090,272 2020-10-11
US202163148038P 2021-02-10 2021-02-10
US63/148,038 2021-02-10
US202163193493P 2021-05-26 2021-05-26
US63/193,493 2021-05-26
PCT/US2021/054084 WO2022076767A1 (en) 2020-10-11 2021-10-08 Methods for treating cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins

Publications (2)

Publication Number Publication Date
JP2023545432A JP2023545432A (ja) 2023-10-30
JP2023545432A5 true JP2023545432A5 (cg-RX-API-DMAC7.html) 2024-10-11

Family

ID=81125466

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023521682A Pending JP2023545432A (ja) 2020-10-11 2021-10-08 191p4d12タンパク質に結合する抗体薬物コンジュゲート(adc)を用いたがんの治療のための方法

Country Status (10)

Country Link
US (1) US20230364254A1 (cg-RX-API-DMAC7.html)
EP (1) EP4225379A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023545432A (cg-RX-API-DMAC7.html)
KR (1) KR20230106607A (cg-RX-API-DMAC7.html)
AU (1) AU2021356542A1 (cg-RX-API-DMAC7.html)
CA (1) CA3198359A1 (cg-RX-API-DMAC7.html)
IL (1) IL302006A (cg-RX-API-DMAC7.html)
MX (1) MX2023004089A (cg-RX-API-DMAC7.html)
TW (1) TW202228788A (cg-RX-API-DMAC7.html)
WO (1) WO2022076767A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202191201A1 (ru) 2018-12-03 2022-01-26 Эдженсис, Инк. Фармацевтические композиции, включающие конъюгаты анти-191p4d12 антитело-лекарственное средство, и способы их применения
CN117982672A (zh) * 2022-07-14 2024-05-07 百奥泰生物制药股份有限公司 抗Nectin-4抗体药物偶联物及应用
WO2024012536A1 (zh) * 2022-07-14 2024-01-18 百奥泰生物制药股份有限公司 抗Nectin-4抗体、其抗体药物偶联物及应用
CN118871132A (zh) * 2023-02-27 2024-10-29 石药集团巨石生物制药有限公司 重组人源化抗Nectin-4单抗-MMAE偶联药物的药物组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2874306T3 (es) * 2010-09-29 2021-11-04 Agensys Inc Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12
CA3111401A1 (en) * 2018-09-19 2020-03-26 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
EA202191201A1 (ru) * 2018-12-03 2022-01-26 Эдженсис, Инк. Фармацевтические композиции, включающие конъюгаты анти-191p4d12 антитело-лекарственное средство, и способы их применения
AU2020241963B2 (en) * 2019-03-17 2026-07-02 Vasgene Therapeutics Inc Treatment of cancers using sEphB4-HSA fusion proteins
EP4013795A4 (en) * 2019-08-13 2023-11-15 Agensys, Inc. TREATMENT OF CANCERS WITH ANTIBODY-DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS
JP2023542879A (ja) * 2020-09-17 2023-10-12 アジェンシス,インコーポレイテッド 191p4d12タンパク質に結合する抗体薬物複合体(adc)を用いたがんの治療方法

Similar Documents

Publication Publication Date Title
US20260098085A1 (en) Methods for treating age-related macular degeneration
US20240325530A1 (en) Combination therapies
US10792370B2 (en) Antibody-drug conjugate
BR112021008778A2 (pt) Métodos de tratamento da oftalmopatia de graves usando anticorpos anti-fcrn
WO2019096194A1 (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
JP2009533456A (ja) 眼疾患処置のためのil−1抗体の使用
TW201249460A (en) Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of B-cell malignancies symptoms
JP2024133544A5 (cg-RX-API-DMAC7.html)
JP2023542879A5 (cg-RX-API-DMAC7.html)
JP2025501978A5 (cg-RX-API-DMAC7.html)
JP2022513684A5 (cg-RX-API-DMAC7.html)
JP2021518394A5 (cg-RX-API-DMAC7.html)
JP2022513386A5 (cg-RX-API-DMAC7.html)
WO2023061472A1 (zh) 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途
JP2021523233A5 (cg-RX-API-DMAC7.html)
KR20200010472A (ko) 항-cd19 항체 및 베네토클락스 조합 치료에 대한 치료 패러다임
WO2018005967A1 (en) Compositions for treating amyloidosis
JP2023500697A5 (cg-RX-API-DMAC7.html)
CN102834413A (zh) 代谢障碍的治疗
JP2024534012A5 (cg-RX-API-DMAC7.html)
WO2024044782A1 (en) Actrii antibody fixed unit dose treatments
WO2011090005A1 (ja) 大腸癌の治療用医薬および治療方法
CN115957321A (zh) 一种抗her2抗体在制备治疗癌症的药物中的用途
WO2021060425A1 (ja) 全身性強皮症治療用医薬組成物
WO2024183622A1 (zh) 一种抗her2抗体在制备治疗癌症的药物中的用途